Herpes Simplex vs Herpes Zoster: Key Differences in Treatment and Management
Herpes simplex virus (HSV) and varicella-zoster virus (VZV/herpes zoster) require fundamentally different treatment approaches: HSV typically needs shorter courses of antivirals (5-10 days) with options for suppressive therapy in recurrent cases, while herpes zoster requires treatment within 72 hours of onset in patients over 50 years to prevent postherpetic neuralgia, and benefits from vaccination strategies that are not available for HSV.
Clinical Presentation and Diagnosis
Herpes Simplex Virus
- HSV causes recurrent, incurable genital or oral infections with grouped vesicles on an erythematous base, often with asymptomatic viral shedding between outbreaks 1
- HSV-1 and HSV-2 are distinct serotypes; HSV-2 causes most recurrent genital infections, while HSV-1 genital infections recur much less frequently 1
- Diagnosis should include virus identification for any new suspected case, with PCR being more sensitive than viral culture 2, 3
- Type-specific serologic testing can determine previous exposure but cannot diagnose acute recurrences 3
Herpes Zoster (Shingles)
- VZV reactivation manifests as dermatomal shingles with severe acute neuralgiform pain, following primary varicella (chickenpox) infection 4
- Clinical diagnosis is usually sufficient, but PCR or antigen detection from lesion swabs can confirm diagnosis when needed 3
- Immunocompromised patients may develop necrotizing, ulcerative, hemorrhagic, or generalized manifestations 4
Treatment Regimens
HSV: First Clinical Episode
For initial genital herpes, treat for 7-10 days with one of the following 1:
- Acyclovir 400 mg orally three times daily, OR
- Acyclovir 200 mg orally five times daily, OR
- Famciclovir 250 mg orally three times daily, OR
- Valacyclovir 1 g orally twice daily
Treatment may be extended if healing is incomplete after 10 days 1
For herpes proctitis or severe oral HSV infection, higher doses (acyclovir 400 mg five times daily) were used in treatment studies 1
HSV: Recurrent Episodes
Episodic treatment is most beneficial when started during prodrome or within 1 day of lesion onset 1. Treat for 5 days with 1:
- Acyclovir 400 mg orally three times daily, OR
- Acyclovir 200 mg orally five times daily, OR
- Acyclovir 800 mg orally twice daily, OR
- Famciclovir 125 mg orally twice daily, OR
- Valacyclovir 500 mg orally twice daily
HSV: Suppressive Therapy
Daily suppressive therapy reduces HSV recurrence frequency by at least 75% in patients with frequent recurrences (≥6 per year) 5. Recommended regimens 1:
- Acyclovir 400 mg orally twice daily, OR
- Famciclovir 250 mg orally twice daily, OR
- Valacyclovir 250-500 mg orally twice daily, OR
- Valacyclovir 1,000 mg orally once daily
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with ≥10 episodes per year 1
After 1 year of continuous suppressive therapy, discontinue to reassess recurrence rate, as frequency decreases over time in many patients 1, 5
HSV: Severe Disease
For disseminated infection, encephalitis, pneumonitis, or hepatitis requiring hospitalization 5:
- Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution
Herpes Zoster Treatment
Antiviral therapy must be initiated within 72 hours of onset in patients aged >50 years or those with severe pain or neurological abnormalities to reduce postherpetic neuralgia likelihood and duration 3
Standard treatment regimens (based on general medical knowledge, as provided evidence focuses on HSV):
- Valacyclovir 1 g orally three times daily for 7 days, OR
- Famciclovir 500 mg orally three times daily for 7 days, OR
- Acyclovir 800 mg orally five times daily for 7 days
Immunocompromised patients require prolonged therapy and close monitoring 6
Key Management Differences
HSV-Specific Considerations
- Suppressive therapy does not eliminate asymptomatic viral shedding or completely prevent transmission 5
- Patients should abstain from sexual activity when lesions or prodromal symptoms are present 1
- Condom use should be encouraged during all sexual exposures, as transmission occurs during asymptomatic periods 1, 5
- Women of childbearing age must inform prenatal care providers about HSV infection due to neonatal transmission risk 5
- Sex partners require evaluation and counseling even if asymptomatic 1
Herpes Zoster-Specific Considerations
- The 72-hour treatment window is critical—early intervention prevents postherpetic neuralgia 3
- Pain management is a primary treatment goal, unlike HSV where symptom control and transmission prevention are priorities 4
- Vaccination is available and highly effective for prevention 7
- The recombinant zoster vaccine (RZV/Shingrix) is preferred over live zoster vaccine, with 91.3% efficacy against herpes zoster and 88.8% against postherpetic neuralgia in patients ≥70 years 7
Special Populations
HIV-Infected Patients
Both HSV and VZV infections may be prolonged, severe, and atypical in immunocompromised hosts 1, 4
For HSV in HIV patients 1:
- Higher doses are beneficial: acyclovir 400 mg orally 3-5 times daily
- Famciclovir 500 mg twice daily is effective for decreasing recurrences and subclinical shedding
- Continue therapy until clinical resolution
Critical warning: Valacyclovir 8 g/day has been associated with hemolytic uremic syndrome or thrombotic thrombocytopenic purpura in immunocompromised patients, though recommended doses for genital herpes are safe 1
Resistance Considerations
Acyclovir-resistant HSV strains occur with suppressive therapy but have not been associated with treatment failure in immunocompetent patients 5
In immunocompromised patients, acyclovir resistance is increasingly recognized, particularly with long-term administration 8. Foscarnet is the alternative when resistance is confirmed or suspected 6
Common Pitfalls to Avoid
Do not delay herpes zoster treatment beyond 72 hours—efficacy for preventing postherpetic neuralgia drops significantly 3
Do not use topical acyclovir for either condition—it is substantially less effective than systemic therapy 1
Do not assume HSV suppressive therapy prevents all transmission—asymptomatic shedding still occurs 5
Do not use commercially available HSV type-specific antibody tests without understanding their limitations—false positives occur even at index values >3.5, and confirmatory testing may be needed 9
Do not treat recurrent HSV in immunocompetent patients unless therapy can be initiated during prodrome or within 1 day of onset—late treatment provides minimal benefit 1